SCHEMBL26401753

SCHEMBL26401753

COc1cnc(Oc2c(Cl)cc([N+](=O)[O-])cc2Cl)cc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
LMNA P02545 6/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
HPGD P15428 3/20 0.40
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPK1 P28482 2/20 0.39
HTT P42858 3/20 0.37
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
PIN1 Q13526 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23691262 0.86 MAPT (0.41) MAPTLMNASMN1; SMN2HPGDNPC1
SCHEMBL23671355 0.82 MAPT (0.38) MAPTLMNASMN1; SMN2HPGDNPC1
SCHEMBL29965285 0.82 MAPT (0.38) MAPTLMNASMN1; SMN2HPGDNPC1
SCHEMBL23691382 0.82 MAPT (0.38) MAPTLMNASMN1; SMN2HPGDNPC1
SCHEMBL23691438 0.81 MAPT (0.47) MAPTLMNASMN1; SMN2HPGDNPC1
SCHEMBL29966196 0.81 CYP19A1 (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL26402725 0.81 CYP19A1 (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL29965239 0.80 P2RX3 (0.34) MAPTLMNASMN1; SMN2HPGDCYP1A2
SCHEMBL29965505 0.80 MAPT (0.47) MAPTNPC1ALDH1A1POLBMEN1
SCHEMBL23663414 0.80 P2RX3 (0.34) MAPTLMNASMN1; SMN2HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320197-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF ECCOGENE INC (US) 2025-10-16 US disclosed
US-12291518-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE INC. (US) 2025-05-06 US disclosed
CN-115244037-B Substituted triazinones as thyroid hormone receptor agonists 诚益生物(美国)公司 2024-10-25 CN disclosed
US-11780825-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-10-10 US disclosed
US-11780825-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-10-10 US disclosed
US-11780825-B2 Thyroid hormone receptor agonists and use thereof ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-10-10 US disclosed
EP-4090652-A1 SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS Eccogene (Shanghai) Co., Ltd. (CN) 2022-11-23 EP disclosed
CN-115244037-A Substituted triazinones as thyroid hormone receptor agonists 上海诚益生物科技有限公司 2022-10-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780825-B2 Thyroid hormone receptor agonists and use thereof TSHR, THRA, THRB MAPT 112/4885LMNA 2491/4885SMN1; SMN2 3988/4885
US-12291518-B2 Thyroid hormone receptor agonists and use thereof TSHR, THRA, THRB MAPT 112/4885LMNA 2491/4885SMN1; SMN2 3988/4885
US-20250320197-A1 THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF TSHR, THRA, THRB MAPT 112/4885LMNA 2491/4885SMN1; SMN2 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.